168 related articles for article (PubMed ID: 15943472)
21. Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores.
Wang GT; Chen Y; Wang S; Gentles R; Sowin T; Kati W; Muchmore S; Giranda V; Stewart K; Sham H; Kempf D; Laver WG
J Med Chem; 2001 Apr; 44(8):1192-201. PubMed ID: 11312919
[TBL] [Abstract][Full Text] [Related]
22. Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: modifications of essential pyrrolidinone ring substituents.
Brouillette WJ; Bajpai SN; Ali SM; Velu SE; Atigadda VR; Lommer BS; Finley JB; Luo M; Air GM
Bioorg Med Chem; 2003 Jul; 11(13):2739-49. PubMed ID: 12788348
[TBL] [Abstract][Full Text] [Related]
23. Optimization of novel acyl pyrrolidine inhibitors of hepatitis C virus RNA-dependent RNA polymerase leading to a development candidate.
Slater MJ; Amphlett EM; Andrews DM; Bravi G; Burton G; Cheasty AG; Corfield JA; Ellis MR; Fenwick RH; Fernandes S; Guidetti R; Haigh D; Hartley CD; Howes PD; Jackson DL; Jarvest RL; Lovegrove VL; Medhurst KJ; Parry NR; Price H; Shah P; Singh OM; Stocker R; Thommes P; Wilkinson C; Wonacott A
J Med Chem; 2007 Mar; 50(5):897-900. PubMed ID: 17269759
[TBL] [Abstract][Full Text] [Related]
24. A sialic acid-derived phosphonate analog inhibits different strains of influenza virus neuraminidase with different efficiencies.
White CL; Janakiraman MN; Laver WG; Philippon C; Vasella A; Air GM; Luo M
J Mol Biol; 1995 Feb; 245(5):623-34. PubMed ID: 7844831
[TBL] [Abstract][Full Text] [Related]
25. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.
Babu YS; Chand P; Bantia S; Kotian P; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Elliott AJ; Parker CD; Ananth SL; Horn LL; Laver GW; Montgomery JA
J Med Chem; 2000 Sep; 43(19):3482-6. PubMed ID: 11000002
[No Abstract] [Full Text] [Related]
26. Investigation of neuraminidase-substrate recognition using molecular dynamics and free energy calculations.
Masukawa KM; Kollman PA; Kuntz ID
J Med Chem; 2003 Dec; 46(26):5628-37. PubMed ID: 14667217
[TBL] [Abstract][Full Text] [Related]
27. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.
Du QS; Wang SQ; Chou KC
Biochem Biophys Res Commun; 2007 Oct; 362(2):525-31. PubMed ID: 17707775
[TBL] [Abstract][Full Text] [Related]
28. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.
Chand P; Kotian PL; Dehghani A; El-Kattan Y; Lin TH; Hutchison TL; Babu YS; Bantia S; Elliott AJ; Montgomery JA
J Med Chem; 2001 Dec; 44(25):4379-92. PubMed ID: 11728184
[TBL] [Abstract][Full Text] [Related]
29. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands.
Wei DQ; Du QS; Sun H; Chou KC
Biochem Biophys Res Commun; 2006 Jun; 344(3):1048-55. PubMed ID: 16647045
[TBL] [Abstract][Full Text] [Related]
30. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6.
Venkatramani L; Johnson ES; Kolavi G; Air GM; Brouillette WJ; Mooers BH
BMC Struct Biol; 2012 May; 12():7. PubMed ID: 22559154
[TBL] [Abstract][Full Text] [Related]
32. Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding.
Smith BJ; Huyton T; Joosten RP; McKimm-Breschkin JL; Zhang JG; Luo CS; Lou MZ; Labrou NE; Garrett TP
Acta Crystallogr D Biol Crystallogr; 2006 Sep; 62(Pt 9):947-52. PubMed ID: 16929094
[TBL] [Abstract][Full Text] [Related]
33. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
[TBL] [Abstract][Full Text] [Related]
34. Discovery, structure-activity relationship, and pharmacological evaluation of (5-substituted-pyrrolidinyl-2-carbonyl)-2-cyanopyrrolidines as potent dipeptidyl peptidase IV inhibitors.
Pei Z; Li X; Longenecker K; von Geldern TW; Wiedeman PE; Lubben TH; Zinker BA; Stewart K; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Long M; Wells H; Kempf-Grote AJ; Madar DJ; McDermott TS; Bhagavatula L; Fickes MG; Pireh D; Solomon LR; Lake MR; Edalji R; Fry EH; Sham HL; Trevillyan JM
J Med Chem; 2006 Jun; 49(12):3520-35. PubMed ID: 16759095
[TBL] [Abstract][Full Text] [Related]
35. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases.
Wang SQ; Du QS; Chou KC
Biochem Biophys Res Commun; 2007 Mar; 354(3):634-40. PubMed ID: 17266937
[TBL] [Abstract][Full Text] [Related]
36. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.
Kim CU; Lew W; Williams MA; Liu H; Zhang L; Swaminathan S; Bischofberger N; Chen MS; Mendel DB; Tai CY; Laver WG; Stevens RC
J Am Chem Soc; 1997 Jan; 119(4):681-90. PubMed ID: 16526129
[TBL] [Abstract][Full Text] [Related]
37. Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics.
Hanessian S; Yun H; Hou Y; Yang G; Bayrakdarian M; Therrien E; Moitessier N; Roggo S; Veenstra S; Tintelnot-Blomley M; Rondeau JM; Ostermeier C; Strauss A; Ramage P; Paganetti P; Neumann U; Betschart C
J Med Chem; 2005 Aug; 48(16):5175-90. PubMed ID: 16078837
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
39. On three-dimensional holographic vector of atomic interaction field analysis for influenza neuraminidase inhibitors.
Li ZS; Sun JY; Liang GZ; Lu FL; Zhu WP; Zhang MJ; Zhang Y; Yang SB; Shu M; Chen GH; Lu TT
Chem Biol Drug Des; 2009 Feb; 73(2):236-43. PubMed ID: 19207426
[TBL] [Abstract][Full Text] [Related]
40. Prolyl oligopeptidase inhibition by N-acyl-pro-pyrrolidine-type molecules.
Kánai K; Arányi P; Böcskei Z; Ferenczy G; Harmat V; Simon K; Bátori S; Náray-Szabo G; Hermecz I
J Med Chem; 2008 Dec; 51(23):7514-22. PubMed ID: 19006380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
